KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Financing Activities: 2016-2024

Historic Cash from Financing Activities for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to -$211.8 million.

  • Amneal Pharmaceuticals' Cash from Financing Activities rose 164.37% to $59.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.6 million, marking a year-over-year increase of 67.14%. This contributed to the annual value of -$211.8 million for FY2024, which is 0.37% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Cash from Financing Activities of -$211.8 million as of FY2024, which was up 0.37% from -$212.6 million recorded in FY2023.
  • Amneal Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $131.8 million during FY2020, with a 5-year trough of -$212.6 million in FY2023.
  • For the 3-year period, Amneal Pharmaceuticals' Cash from Financing Activities averaged around -$177.0 million, with its median value being -$211.8 million (2024).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first spiked by 387.58% in 2020, then crashed by 204.79% in 2021.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Cash from Financing Activities stood at $131.8 million in 2020, then crashed by 204.79% to -$138.1 million in 2021, then rose by 22.81% to -$106.6 million in 2022, then tumbled by 99.37% to -$212.6 million in 2023, then grew by 0.37% to -$211.8 million in 2024.